Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$2.82 USD
+0.06 (2.17%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $2.82 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Income Statements
Fiscal Year end for Xeris Biopharma Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 164 | 110 | 50 | 20 | 3 |
Cost Of Goods | 29 | 23 | 13 | 9 | 2 |
Gross Profit | 135 | 88 | 36 | 11 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 179 | 170 | 151 | 95 | 124 |
Income After Depreciation & Amortization | -44 | -82 | -115 | -84 | -122 |
Non-Operating Income | 7 | 1 | 0 | 3 | 4 |
Interest Expense | 27 | 15 | 7 | 11 | 7 |
Pretax Income | -64 | -96 | -123 | -91 | -126 |
Income Taxes | -1 | -1 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -62 | -95 | -123 | -91 | -126 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -62 | -95 | -123 | -91 | -126 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -29 | -68 | -112 | -81 | -120 |
Depreciation & Amortization (Cash Flow) | 15 | 14 | 3 | 2 | 2 |
Income After Depreciation & Amortization | -44 | -82 | -115 | -84 | -122 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 137.68 | 135.63 | 79.03 | 42.64 | 26.11 |
Diluted EPS Before Non-Recurring Items | -0.45 | -0.68 | -1.54 | -2.14 | -4.81 |
Diluted Net EPS (GAAP) | -0.45 | -0.70 | -1.55 | -2.14 | -4.81 |
Fiscal Year end for Xeris Biopharma Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 48.07 | 40.64 | 44.39 | 48.32 | 38.01 |
Cost Of Goods | 7.79 | 5.97 | 7.57 | 8.20 | 7.56 |
Gross Profit | 40.28 | 34.67 | 36.82 | 40.12 | 30.45 |
SG&A, R&D, and Dept/Amort Expenses | 48.46 | 48.91 | 46.66 | 45.03 | 46.44 |
Income After SG&A, R&D, and Dept/Amort Expenses | -8.18 | -14.24 | -9.84 | -4.91 | -15.99 |
Non-Operating Income | 1.90 | 2.60 | 3.23 | -0.77 | 1.99 |
Interest Expense | 7.96 | 7.03 | 7.02 | 6.85 | 6.53 |
Pretax Income | -14.26 | -18.67 | -13.63 | -12.53 | -20.52 |
Income Taxes | 0.75 | 0.31 | -0.24 | -0.34 | -0.68 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -15.01 | -18.98 | -13.39 | -12.19 | -19.84 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -15.01 | -18.98 | -13.39 | -12.19 | -19.84 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 148.35 | 140.51 | 138.13 | 138.06 | 137.34 |
Diluted EPS Before Non-Recurring Items | -0.10 | -0.14 | -0.10 | -0.09 | -0.14 |
Diluted Net EPS (GAAP) | -0.10 | -0.14 | -0.10 | -0.09 | -0.14 |